Success Metrics

Clinical Success Rate
91.2%

Based on 52 completed trials

Completion Rate
91%(52/57)
Active Trials
6(7%)
Results Posted
40%(21 trials)
Terminated
5(6%)

Phase Distribution

Ph phase_1
14
17%
Ph phase_3
9
11%
Ph not_applicable
7
9%
Ph phase_2
7
9%
Ph phase_4
14
17%

Phase Distribution

14

Early Stage

7

Mid Stage

23

Late Stage

Phase Distribution51 total trials
Phase 1Safety & dosage
14(27.5%)
Phase 2Efficacy & side effects
7(13.7%)
Phase 3Large-scale testing
9(17.6%)
Phase 4Post-market surveillance
14(27.5%)
N/ANon-phased studies
7(13.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.2%

52 of 61 finished

Non-Completion Rate

14.8%

9 ended early

Currently Active

6

trials recruiting

Total Trials

81

all time

Status Distribution
Active(7)
Completed(52)
Terminated(9)
Other(13)

Detailed Status

Completed52
unknown13
Terminated5
Withdrawn4
Active, not recruiting4
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
81
Active
6
Success Rate
91.2%
Most Advanced
Phase 4

Trials by Phase

Phase 114 (27.5%)
Phase 27 (13.7%)
Phase 39 (17.6%)
Phase 414 (27.5%)
N/A7 (13.7%)

Trials by Status

unknown1316%
withdrawn45%
completed5264%
active_not_recruiting45%
not_yet_recruiting11%
recruiting22%
terminated56%

Recent Activity

Clinical Trials (81)

Showing 20 of 81 trialsScroll for more
NCT06650501Phase 4

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

Recruiting
NCT04618913

Anticoagulation in Patients With Venous Thromboembolism and Cancer

Active Not Recruiting
NCT05038228

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

Active Not Recruiting
NCT04809818Phase 1

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Completed
NCT07358416

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active Not Recruiting
NCT05838664

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Completed
NCT03463317Phase 4

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Completed
NCT06945276Phase 1

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

Completed
NCT07083609

Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam

Recruiting
NCT04532528

ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years

Completed
NCT03752294Phase 1

A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.

Withdrawn
NCT06449469Not Applicable

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Active Not Recruiting
NCT06818279Phase 2

Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis

Not Yet Recruiting
NCT03996772Phase 3

PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

Completed
NCT04249401

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

Completed
NCT04782076Phase 1

A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

Completed
NCT05064800Phase 1

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Completed
NCT04662515

NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications

Completed
NCT02744092Not Applicable

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Completed
NCT01153698

Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
81